New Proposal for USP Chapter <711> Dissolution Published for Comments
Recommendation
Tuesday, 10 February 2026 13.00 - 17.30 h
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In the Pharmacopeial Forum, PF 48(6), a proposal for a revised USP Chapter <711> Dissolution was published. The proposal is based on the version of the chapter official as of 01 May 2022. The previous proposal published in PF 48(2) in March 2022 was canceled.
The purpose of the revision is to replace USP Prednisone Tablets RS with a new Reference Standard, USP Dissolution Performance Verification Standard-Prednisone RS, to qualify the Dissolution Apparatus 1 and Apparatus 2.
In the briefing notes to the revised chapter, it is pointed out that "the use of USP Prednisone Tablets RS in this general chapter is referenced in The Dissolution Procedure—Development and Validation <1092>. This reference will be updated, using a suitable accelerated revision process, to become official at the same date as this revision."
Comments can be submitted until 31 January 2023. In the absence of significant adverse comments, the new version will be implemented via an Interim Revision Announcement with an official date of 01 May 2023.
The draft of the revised chapter is available on PF Online.
Related GMP News
03.02.2026Your Input is Requested: AQCG Survey on OOS Investigations
03.02.2026Questions and Answers on System Suitability Tests (SST) - Part 2
03.02.2026Eurachem Publishes New Guide on the Fitness for Intended Use of Analytical Equipment and Systems
14.01.2026FDA Warning Letter: OOS Handling and HPLC Method Validation
07.01.2026Revised Ph. Eur. Chapters 2.9.42 and 2.9.43 on Dissolution Testing
07.01.2026Korean MFDS Publishes Data Collection on Dissolution Test Methods